Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Gujarat Themis Biosyn has reported total income of Rs. 50.66 crores during the period ended June 30, 2023
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
Subscribe To Our Newsletter & Stay Updated
